Program
LTZ-232
A development code.
Its studies are mostly in Colonic Neoplasms, led by LTZ Therapeutics.
Furthest: phase 1, since Oct 11, 20261 company-led study, 1 open or runningNext primary completion: Dec 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LTZ Therapeutics | 11 open or running | phase 1since Oct 11, 2026 | Oct 11, 2026 | Dec 2031phase 1 · NCT07878988 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 11, 2026First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07878988 · 152 planned · United States
Ahead
- Dec 2031Primary completion: phase 1 study in Colorectal NeoplasmsNCT07878988
TargetBeta
EPCAM →read by rule
“LTZ-232 is an engineered anti-EPCAM bispecific antibody designed to activate tumor-associated macrophages to phagocytose and kill tumor cells.”study text, by rule · the study
Other programs on EPCAM
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| adecatumumabrule | mirador-therapeutics-inc | phase 2 | 4 |
| Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule | BioNTech | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07878988Colorectal Neoplasms · United States | 1 | Recruiting | Dec 2031 | 152 |
How it is read
Names in the registry
- “LTZ-232”, 1 entry
Codes read as this program: LTZ232.
Conditions, from the studies’ own filings
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.